Lung cancer vaccines.

PubWeight™: 0.82‹?›

🔗 View Article (PMC 3196521)

Published in Cancer J on September 28, 2011

Authors

Ronan J Kelly1, Giuseppe Giaccone

Author Affiliations

1: Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1457, USA.

Associated clinical trials:

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | NCT00480025

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP) | NCT00676507

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (START) | NCT00409188

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV (NSCLC) | NCT00516685

Articles cited by this

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Dendritic cells and the control of immunity. Nature (1998) 56.54

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol (2000) 9.76

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94

Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31

Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 5.56

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10

Transforming growth factor-beta: biological function and chemical structure. Science (1986) 5.08

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol (1999) 4.65

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46

Lymphocyte-mediated cytotoxicity. Annu Rev Immunol (2001) 4.37

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med (1994) 4.20

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell (2004) 3.55

Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29

The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 3.06

Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res (1993) 3.02

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.90

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90

The TGF-beta family of growth and differentiation factors. Cell (1987) 2.86

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 2.73

Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol (1997) 2.62

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 2.27

The cancer vaccine roller coaster. Nat Biotechnol (2009) 2.26

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol (2005) 2.25

TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev (2003) 2.20

Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol (2002) 2.04

Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg (2007) 1.99

Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem (2003) 1.98

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med (1998) 1.91

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer (1997) 1.86

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A (2001) 1.85

MUC1 immunobiology: from discovery to clinical applications. Adv Immunol (2004) 1.79

Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol (1989) 1.72

Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res (1995) 1.51

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther (2006) 1.43

Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem (2001) 1.36

Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res (2003) 1.34

MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem (2004) 1.33

Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28

A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res (1999) 1.28

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med (2003) 1.27

MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis (2005) 1.23

Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer (1999) 1.23

Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol (2004) 1.18

Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg (2004) 1.17

Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol (2000) 1.11

Cancer vaccines and immunotherapy. Br Med Bull (2002) 1.07

Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother (2003) 1.07

Lung cancer immunotherapy. Clin Med Res (2005) 1.04

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer (2007) 1.03

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother (1996) 1.00

Cancer vaccines: an old idea comes of age. Cancer Biol Ther (2003) 1.00

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin (2007) 0.98

Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol (2008) 0.97

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother (1993) 0.97

The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol (2004) 0.95

Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother (2005) 0.93

Understanding the cell biology of antigen presentation: the dendritic cell contribution. Curr Opin Cell Biol (2003) 0.92

The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology (2001) 0.91

Prognostic significance of cytokine modulation in non-small cell lung cancer. Int J Cancer (2002) 0.90

Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother (2002) 0.88

Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med (2003) 0.87

Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol (2004) 0.87

Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg (2009) 0.87

Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer (1994) 0.86

Anticancer vaccination strategies. Ann Oncol (2004) 0.80

Immunohistochemical detection of intercellular adhesion molecule-1 (ICAM-1) and major histocompatibility complex class I antigens in seminoma. J Urol (1993) 0.77

Articles by these authors

(truncated to the top 100)

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15

Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04

Cell death independent of caspases: a review. Clin Cancer Res (2005) 3.85

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol (2011) 3.73

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol (2013) 3.71

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn (2013) 2.71

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol (2003) 2.62

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res (2003) 2.44

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res (2012) 2.26

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J Clin Oncol (2002) 2.18

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol (2005) 2.15

An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03

Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99

Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97

Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96

MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol (2002) 1.72

Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer (2006) 1.67

Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol (2007) 1.60

Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood (2010) 1.56

Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56

Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol (2006) 1.52

EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol (2007) 1.48

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A (2010) 1.45

Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol (2008) 1.44

CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44

Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer (2006) 1.43

How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging (2006) 1.41

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer (2007) 1.38

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol (2008) 1.37

Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36

TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther (2007) 1.34

Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res (2004) 1.34

Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer (2006) 1.33

Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell (2006) 1.33

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 1.32

Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol (2005) 1.30

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 1.30

Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther (2006) 1.28

STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 1.27

Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res (2012) 1.23

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer (2007) 1.21

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res (2012) 1.21

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.21

Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20

Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer (2009) 1.20

A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract (2011) 1.16

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res (2011) 1.16

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer (2014) 1.15

Expression and mutational status of c-kit in thymic epithelial tumors. J Thorac Oncol (2010) 1.15

Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 1.12

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res (2010) 1.12

Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther (2007) 1.11

Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl (2007) 1.10

Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. Exp Cell Res (2004) 1.08

Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res (2002) 1.08

EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol (2011) 1.07

The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol (2004) 1.06

Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol (2005) 1.05

Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer (2010) 1.04

Treatment of advanced thymoma and thymic carcinoma. Curr Treat Options Oncol (2009) 1.04

Homodimerization antagonizes nuclear export of survivin. Traffic (2007) 1.04

Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies. Int J Cancer (2005) 1.03

The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol (2013) 1.00

Biology and management of malignant pleural mesothelioma. Eur J Cancer (2006) 1.00

The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol (2006) 1.00

Targeted agents: how to select the winners in preclinical and early clinical studies? Eur J Cancer (2011) 0.99

Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res (2003) 0.99

MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One (2011) 0.99

EGFR inhibitors in lung cancer. Oncology (Williston Park) (2005) 0.98

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol (2014) 0.98

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol (2014) 0.98

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol (2010) 0.96

Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res (2011) 0.96

Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl) (2014) 0.96

Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A (2012) 0.96

Neuroendocrine ACTH-producing tumor of the thymus--experience with 12 patients over 25 years. J Clin Endocrinol Metab (2012) 0.95

Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol (2010) 0.95

Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des (2007) 0.95